Merrill S Kies

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. ncbi request reprint Cetuximab (Imclone/Merck/Bristol-Myers Squibb)
    Merrill S Kies
    University of Texas MD Anderson Cancer Center, Houston 77030, USA
    Curr Opin Investig Drugs 3:1092-100. 2002
  2. ncbi request reprint Cetuximab in cancers of the lung and head & neck
    Edward S Kim
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Semin Oncol 31:61-7. 2004
  3. ncbi request reprint ZD1839 (Iressa) in non-small cell lung cancer
    Roy S Herbst
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Oncologist 7:9-15. 2002
  4. ncbi request reprint Is concurrent chemoradiation the treatment of choice for all patients with Stage III or IV head and neck carcinoma?
    Adam S Garden
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 100:1171-8. 2004
  5. ncbi request reprint Induction chemotherapy for squamous cancer of the head and neck
    Merrill S Kies
    Department of Thoracic Head and Neck Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Curr Oncol Rep 9:129-33. 2007
  6. ncbi request reprint Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial
    Ritsuko Komaki
    Department of Radiation Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 58:1369-77. 2004
  7. pmc Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial
    Merrill S Kies
    Departments of Thoracic Head and Neck Medical Oncology, Head and Neck Surgery, Radiation Oncology, Biostatistics, Radiology, and Pathology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 28:8-14. 2010
  8. ncbi request reprint Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/resistant nonsmall cell lung carcinoma
    Edward S Kim
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77401, USA
    Cancer 104:561-9. 2005
  9. ncbi request reprint Radiation-induced xerostomia in patients with head and neck cancer: pathogenesis, impact on quality of life, and management
    Mark S Chambers
    Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, USA
    Head Neck 26:796-807. 2004
  10. ncbi request reprint Sinonasal malignancies with neuroendocrine differentiation: patterns of failure according to histologic phenotype
    David I Rosenthal
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 101:2567-73. 2004

Detail Information

Publications49

  1. ncbi request reprint Cetuximab (Imclone/Merck/Bristol-Myers Squibb)
    Merrill S Kies
    University of Texas MD Anderson Cancer Center, Houston 77030, USA
    Curr Opin Investig Drugs 3:1092-100. 2002
    ..In May 2002, Lehman Brothers predicted global peak sales of US $2 billion [454652], while in the same month, Bear Stearns estimated that sales for Merck KGaA would reach 285 million Euros in 2007 [453500]...
  2. ncbi request reprint Cetuximab in cancers of the lung and head & neck
    Edward S Kim
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Semin Oncol 31:61-7. 2004
    ..Ultimately, these therapies may become valuable contributors in the treatment of head and neck cancer and lung cancer. This report will focus specifically on the epidermal growth factor receptor and cetuximab...
  3. ncbi request reprint ZD1839 (Iressa) in non-small cell lung cancer
    Roy S Herbst
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Oncologist 7:9-15. 2002
    ..This review summarizes the currently available clinical data on the use of ZD1839 in the treatment of NSCLC...
  4. ncbi request reprint Is concurrent chemoradiation the treatment of choice for all patients with Stage III or IV head and neck carcinoma?
    Adam S Garden
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 100:1171-8. 2004
    ....
  5. ncbi request reprint Induction chemotherapy for squamous cancer of the head and neck
    Merrill S Kies
    Department of Thoracic Head and Neck Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Curr Oncol Rep 9:129-33. 2007
    ..These regimens consist of initial systemic chemotherapy, known as neoadjuvant or induction chemotherapy, followed by radiation with or without concomitant chemotherapy...
  6. ncbi request reprint Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial
    Ritsuko Komaki
    Department of Radiation Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 58:1369-77. 2004
    ..To determine the ability of amifostine to reduce the severity and/or incidence of the acute toxicities of concurrent chemotherapy and radiotherapy (RT) for non-small-cell lung cancer...
  7. pmc Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial
    Merrill S Kies
    Departments of Thoracic Head and Neck Medical Oncology, Head and Neck Surgery, Radiation Oncology, Biostatistics, Radiology, and Pathology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 28:8-14. 2010
    ..PFS is promising, and this sequential treatment strategy should be further investigated. Patients with HPV-positive tumors have an excellent prognosis...
  8. ncbi request reprint Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/resistant nonsmall cell lung carcinoma
    Edward S Kim
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77401, USA
    Cancer 104:561-9. 2005
    ....
  9. ncbi request reprint Radiation-induced xerostomia in patients with head and neck cancer: pathogenesis, impact on quality of life, and management
    Mark S Chambers
    Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, USA
    Head Neck 26:796-807. 2004
    ..Xerostomia is a common, debilitating complication of radiation therapy (RT) for head and neck cancer. This article reviews the pathogenesis of radiation-induced xerostomia, its impact on quality of life (QOL), and treatment options...
  10. ncbi request reprint Sinonasal malignancies with neuroendocrine differentiation: patterns of failure according to histologic phenotype
    David I Rosenthal
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 101:2567-73. 2004
    ..The authors reviewed their institutional experience to determine whether sinonasal neuroendocrine tumors of different histologies have distinct clinical characteristics that warrant individualized treatment approaches...
  11. ncbi request reprint Neoadjuvant chemotherapy for squamous cell carcinoma of the oral tongue in young adults: a case series
    Erich M Sturgis
    Department of Head and Neck Surgery, Unit 441, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030 4009, USA
    Head Neck 27:748-56. 2005
    ....
  12. ncbi request reprint Measuring head and neck cancer symptom burden: the development and validation of the M. D. Anderson symptom inventory, head and neck module
    David I Rosenthal
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Head Neck 29:923-31. 2007
    ....
  13. ncbi request reprint Gefitinib: current and future status in cancer therapy
    Roy S Herbst
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Adv Hematol Oncol 1:466-72. 2003
    ..This article provides a detailed overview of gefitinib, the rationale for its use in a wide range of tumor types, and the current clinical development status of this novel agent...
  14. ncbi request reprint Head and neck cancer: integrating anti-EGFR treatment with standard therapy
    Merrill S Kies
    Department of Thoracic Head and Neck Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Natl Compr Canc Netw 2:S52-9. 2004
    ..Novel agents that target the epidermal growth factor receptor have shown particular promise in the management of squamous cell carcinoma of the head and neck...
  15. ncbi request reprint The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: potential for decreased toxicity and combination with biological therapy
    Roy S Herbst
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Cancer 95:340-53. 2002
    ..The authors conducted a formal Phase II trial to evaluate the efficacy of this combination in both untreated and previously treated patients with Stage IIIB (with pleural effusion) or Stage IV NSCLC...
  16. doi request reprint A phase II study of Lonafarnib (SCH66336) in patients with chemorefractory, advanced squamous cell carcinoma of the head and neck
    Emer O Hanrahan
    Department of Thoracic Head and Neck Medical Oncology, MD Anderson Cancer Center, University of Texas, Houston, TX 77030, USA
    Am J Clin Oncol 32:274-9. 2009
    ..A phase II study of lonafarnib was conducted to determine its efficacy and safety in patients with recurrent, platinum-refractory SCCHN...
  17. ncbi request reprint Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer
    George R Blumenschein
    Department of Thoracic and Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Invest New Drugs 26:81-7. 2008
    ..Oral vorinostat 400 mg qd was generally well tolerated but did not demonstrate efficacy as defined by tumor response in this small group of heavily pre-treated patients...
  18. doi request reprint Videos in clinical medicine. Examination of the larynx and pharynx
    F Christopher Holsinger
    Department of Head and Neck Surgery, University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    N Engl J Med 358:e2. 2008
  19. ncbi request reprint Induction chemotherapy for head and neck squamous cell carcinomas (SCCHN)
    Merrill S Kies
    Department of Thoracic Head and Neck Medical Oncology, University of Texas, Houston, TX 77230 1402, USA
    Curr Treat Options Oncol 8:252-60. 2007
    ..We await the results of these trials before we accept induction chemotherapy as a standard treatment and to best identify the subgroups of patients who may be most likely to benefit from the approach...
  20. ncbi request reprint Phase I/II study of docetaxel, cisplatin, and concomitant boost radiation for locally advanced squamous cell cancer of the head and neck
    Anne S Tsao
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 24:4163-9. 2006
    ....
  21. ncbi request reprint Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck
    James A Bonner
    Department of Medicine, University of Alabama, Birmingham, USA
    N Engl J Med 354:567-78. 2006
    ....
  22. ncbi request reprint Phase II trial of taxol in salivary gland malignancies (E1394): a trial of the Eastern Cooperative Oncology Group
    Jill Gilbert
    Louisiana State University Medical Center, New Orleans, Louisiana, USA
    Head Neck 28:197-204. 2006
    ..The Eastern Cooperative Oncology Group (ECOG) initiated a phase II evaluation of paclitaxel in patients with locally recurrent or metastatic salivary gland malignancies...
  23. ncbi request reprint Asian ethnicity as a predictor of response in patients with non-small-cell lung cancer treated with gefitinib on an expanded access program
    Sheeba K Thomas
    Department of Lymphoma Myeloma, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Lung Cancer 7:326-31. 2006
    ..The primary objective of this retrospective study was to investigate the potential role of East Asian ethnicity or origin in predicting response to gefitinib in advanced-stage non-small-cell lung cancer (NSCLC)...
  24. ncbi request reprint High survival and organ function rates after primary chemoradiotherapy for intermediate-stage squamous cell carcinoma of the head and neck treated in a multicenter phase II trial
    Ezra E W Cohen
    Section of Hematology Oncology, Department of Medicine, University of Chicago, Chicago, IL, 60637, USA
    J Clin Oncol 24:3438-44. 2006
    ..This study was undertaken to assess whether shortening treatment duration with hyperfractionated RT would be feasible and improve locoregional control, organ preservation, and progression-free survival...
  25. ncbi request reprint Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer
    Michael A Carducci
    Division of Medical Oncology, Kimmel Cancer Center at Johns Hopkins, Baltimore, MD, USA
    J Clin Oncol 24:4092-9. 2006
    ..Secondary objectives were maximum-tolerated dose (MTD), pharmacokinetics (PK), toxicity, and response...
  26. ncbi request reprint Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer
    Mark A Socinski
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA
    J Clin Oncol 20:1335-43. 2002
    ..To compare four cycles of therapy versus continuous therapy to determine the optimal duration of chemotherapy in advanced non-small-cell lung cancer (NSCLC)...
  27. ncbi request reprint Differential expression of hormonal and growth factor receptors in salivary duct carcinomas: biologic significance and potential role in therapeutic stratification of patients
    Michelle D Williams
    Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Am J Surg Pathol 31:1645-52. 2007
    ....
  28. ncbi request reprint Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab
    Desmond Curran
    Omega Research, Dublin, Ireland
    J Clin Oncol 25:2191-7. 2007
    ..In this randomized, phase III study, quality of life (QoL) was assessed in patients with locoregionally advanced squamous cell carcinoma of the head and neck (SCCHN) after high-dose radiotherapy alone or in combination with cetuximab...
  29. ncbi request reprint Postoperative treatment intensification for improving outcome in the high-risk patient: an evolutionary process
    Randal S Weber
    Head Neck 27:841-2. 2005
  30. ncbi request reprint New treatments in head and neck cancer
    Merrill S Kies
    University of Texas M D Anderson Cancer Center, USA
    Clin Adv Hematol Oncol 3:92-3. 2005
  31. ncbi request reprint Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck
    Dong M Shin
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 95:322-30. 2002
    ..We also hypothesized that improved complete response (CR) rates with the induction chemotherapy may render better survival rates with subsequently delivered definitive local treatment...
  32. ncbi request reprint Phase I trial of oral estramustine and 3-hr infusional paclitaxel for the treatment of hormone refractory prostate cancer
    Timothy M Kuzel
    Division of Hematology Oncology, Department of Medicine, Robert H Lurie Comprehensive Cancer Center of Northwestern University Medical School, 676 N St Clair, Suite 850, Chicago, IL 60611, USA
    Cancer Invest 20:634-43. 2002
    ..Significant anti-tumor activity has been reconfirmed despite the change in schedule of administration of the paclitaxel...
  33. ncbi request reprint Second-line, low-dose, weekly paclitaxel in patients with stage IIIB/IV nonsmall cell lung carcinoma who fail first-line chemotherapy with carboplatin plus paclitaxel
    Mark A Socinski
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, 27599, USA
    Cancer 95:1265-73. 2002
    ..The authors sought to determine the activity of second-line, low-dose, weekly paclitaxel in patients with NSCLC who failed first-line chemotherapy with carboplatin plus paclitaxel...
  34. ncbi request reprint Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer
    Everett E Vokes
    Department of Medicine, Section of Hematology Oncology, University of Chicago IL 60637 1470, USA
    J Clin Oncol 21:320-6. 2003
    ..Locoregional and distant failure rates were 13% and 23%, respectively. To reduce distant failure rates, we added a brief course of induction chemotherapy to TFHX...
  35. ncbi request reprint Phase I/II trial of vinorelbine and divided-dose carboplatin in advanced non-small cell lung cancer
    Gregory A Masters
    Thoracic Oncology Program, Northwestern University Medical School, Evanston Northwestern Healthcare, 2650 Ridge Avenue, Evanston, IL 60201, USA
    Lung Cancer 39:221-6. 2003
    ..Weekly vinorelbine 25 mg/m(2) and divided-dose carboplatin AUC 2.5 is a well tolerated regimen with activity in advanced NSCLC patients. Further evaluation of this regimen in combination with novel targeted biologic therapy is warranted...
  36. ncbi request reprint Multicenter randomized Phase II study of paclitaxel (1-hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin for advanced head and neck cancer
    Fred R Rosen
    Department of Medicine, Section of Hematology Oncology, University of Illinois at Chicago, 60637, USA
    Clin Cancer Res 9:1689-97. 2003
    ....
  37. ncbi request reprint Intensive concurrent chemoradiotherapy for head and neck cancer with 5-Fluorouracil- and hydroxyurea-based regimens: reversing a pattern of failure
    Athanassios Argiris
    Division of Hematology Oncology, Northwestern University, The Feinberg School of Medicine and the Robert H Lurie Comprehensive Cancer Center, Chicago, Illinois 60611, USA
    Oncologist 8:350-60. 2003
    ..The incorporation of induction chemotherapy may improve the results of treatment by targeting systemic micrometastatic disease...
  38. ncbi request reprint Intraarterial cisplatin with intravenous paclitaxel and ifosfamide as an organ-preservation approach in patients with paranasal sinus carcinoma
    Vassiliki A Papadimitrakopoulou
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 98:2214-23. 2003
    ....
  39. ncbi request reprint Neck dissection in the combined-modality therapy of patients with locoregionally advanced head and neck cancer
    Athanassios Argiris
    The Feinberg School of Medicine and the Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA
    Head Neck 26:447-55. 2004
    ..The purpose of this study was to evaluate the role of neck lymph node (ND) in the combined dissection modality therapy for locoregionally advanced head and neck...
  40. ncbi request reprint Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumors
    Fadlo R Khuri
    Winship Cancer Institute, Emory University, Atlanta, Georgia 30322, USA
    Clin Cancer Res 10:2968-76. 2004
    ....
  41. ncbi request reprint Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck
    Roy S Herbst
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Unit 432, PO Box 301402, Houston, TX 77230 1402, USA
    J Clin Oncol 23:5578-87. 2005
    ....
  42. ncbi request reprint Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results
    Hope S Rugo
    University of California, San Francisco Comprehensive Cancer Center, USA
    J Clin Oncol 23:5474-83. 2005
    ....
  43. ncbi request reprint Competing causes of death and second primary tumors in patients with locoregionally advanced head and neck cancer treated with chemoradiotherapy
    Athanassios Argiris
    The Feinberg School of Medicine and the Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL 60611, USA
    Clin Cancer Res 10:1956-62. 2004
    ....
  44. ncbi request reprint Differential expression of p63 isotypes (DeltaN and TA) in salivary gland neoplasms: biological and diagnostic implications
    Shin ichiro Maruya
    Department of Pathology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Hum Pathol 36:821-7. 2005
    ....
  45. doi request reprint Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study
    Ezra E W Cohen
    Section of Hematology Oncology, Department of Medicine, University of Chicago Division of Biological Sciences, 5801 S Ellis, Chicago, IL 60637, USA
    J Clin Oncol 26:4708-13. 2008
    ..This multi-institutional study assessed the activity and safety of axitinib, an oral, potent, and selective inhibitor of vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3 in patients with advanced thyroid cancer...
  46. ncbi request reprint Merkel cell carcinoma of the tongue and head and neck oral mucosal sites
    Sue S Yom
    Department of Radiation Oncology, of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod 101:761-8. 2006
    ..Mucosal MCC is aggressive, and there is a high risk for local recurrence and regional and distant metastasis. Fulminating courses are often seen. We discuss our treatment policies based on the current literature...
  47. ncbi request reprint Head and neck cancers
    Arlene A Forastiere
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, USA
    J Natl Compr Canc Netw 3:316-91. 2005
  48. ncbi request reprint Implications of methylation patterns of cancer genes in salivary gland tumors
    Michelle D Williams
    Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Clin Cancer Res 12:7353-8. 2006
    ..We investigated the methylation status and protein expression of four tumor suppressor genes to determine their role in salivary gland tumorigenesis...
  49. ncbi request reprint An exploration of the pretreatment coping strategies of patients with carcinoma of the head and neck
    Marcy A List
    Department of Medicine, University of Chicago, Chicago, Illinois 60637, USA
    Cancer 95:98-104. 2002
    ..Understanding how patients cope with these challenges is important in comprehensive care of patients with HNC...